18 June 2014

Directorate Change

Merrion Pharmaceuticals Plc (Merrion or the Company) announces today that Michael Donnelly will not run for re-election at the AGM scheduled for 16 July 2014. Michael will continue to be associated with Merrion in a consultancy capacity and retains his significant shareholding in Merrion through options and warrants.

Michael co-founded Merrion following the acquisition of certain drug delivery technologies from Elan Pharmaceutical plc in 2003. Following the 2007 Initial Public Offering on the Enterprise Securities Market of the Irish Stock Exchange, Merrion went through a number of restructuring events and in June 2012 Michael assumed the role of Executive Chairman. Given the progress made by Merrion as referenced in the 2013 Annual Report, Michael considers it an appropriate time to step back his involvement with the Company which also affords him the opportunity to further pursue his career in the Law.

Dr. Michael McKenna, Chairman of the Board, commented, The Merrion Board and I want to thank Michael for his ten years of dedicated service to Merrion. We highly value his participation as a Director since the inception of the Company and we wish him success in his next venture.

distributed by